PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Athletes of all levels, from grassroots through to elite professional, dream of being the best they can be. Or "The Best" full stop. With the VegaV sports training system, this can become a reality. The first of its kind, VegaV uses special and specific light levels to manipulate the pathways between the eyes and brain, which speeds up the reaction times of the user. After training in the VegaV system, participants' levels of concentration and awareness are greatly increased, meaning that they are able to react to moving objects much faster than they could before, hitting and catching balls at much higher speeds.
days to go:
Expired
investment:
£15,450
Meetzoo is a mobile app that is designed to help people manage their business meetings and time more effectively. Meetzoo users can see information about people they meet, whether they've met before, collaborate on agenda items, notes and quickly see any outstanding actions from previous meetings.
days to go:
Expired
investment:
£144,640
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.
days to go:
Expired
investment:
£70,900
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.
days to go:
Expired
investment:
£49,990
Novus aspires to become the UK's first ethical digital bank. It argues that Generation Z and millennials want purpose-driven products and services that can also address environmental and social challenges of the times. The company asserts that its services align with the aforementioned objective. Novus allows its members to live a sustainable lifestyle by providing them access to sustainable brands through Novus' in-app marketplace and rewarding them via cashbacks. The company intends to undergo two more funding rounds – Series A and Series B – for scaling its UK operations and expanding in the US and other key EU markets within the next two years. It will IPO its business when it achieves profitability. The company also foresees a strategic exit to interested banking entities.
days to go:
Expired
investment:
£732,000
Genuine Impact is the next generation financial terminal made exclusively to empower DIY investors by providing experts with automation tools, portfolio enhancer, unbiased data and insights. Genuine Impact is more cost-effective in comparison with traditional financial terminals, and it makes financial research effortless and efficient. Currently, the company's beta app has 500+ users from more than 27 countries. With the proceeds, the fund raised will be used for new product development, enhancement of existing product and for marketing and branding.
days to go:
Expired
investment:
£500,920
